We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Neutrophil-Lymphocyte Ratio Proves Possible Biomarker for ED

By LabMedica International staff writers
Posted on 30 May 2019
Erectile dysfunction is described as the impotency to obtain or sustain an erection sufficiently in order to enable convincing sexual intercourse. More...
Erectile dysfunction (ED) is estimated to affect about 75% of men over the age of 75 and 20% of men over the age of 20.

The association among many diseases, inflammatory markers and also their roles in the disease etiopathogenesis are important. The literature reveals that emerge and severity of ED are related with markers and mediators of inflammation and endothelial dysfunction.

Urologists at the Ordu University (Ordu, Turkey) and their colleagues evaluated 90 patients with erectile dysfunction (ED) and 94 healthy subjects from their internal medicine and urology clinics. As diagnosis criteria, they used the first five questions of International Index for Erectile Function. The duration of erectile dysfunction was asked and recorded. Height, weight and waist circumference of patients were measured.

The team performed total blood count, sedimentation, C-reactive protein, blood urea nitrogen (BUN), creatine, cholesterol, Low-density lipoprotein cholesterol (LDL-C) and High-density lipoprotein cholesterol (HDL-C) measurements of the patients were recorded. The neutrophil-lymphocyte ratio (NLR) was computed as the total neutrophil count separated by the total lymphocyte count.

The investigators found that there were statistically significant differences in terms of NLR between the control 1.038 (range: 0.507-1.92) and ED 2.38 (1.67.0-3.00) groups. According to the multivariate logistic regression analysis, duration of ED (Cut off: 7.5 month) predicted ED with 78.8% sensitivity and 63.1% specificity (AUC: < 0.001). Moreover, NLR (Cut off: 1.574) predicted ED with 81.8% sensitivity and 67.0% specificity (AUC: < 0.001) according to the multivariate logistic regression analysis.

The authors concluded that that the neutrophil-lymphocyte ratio was higher in patient group than the control group, and that the neutrophil-lymphocyte ratio (NLR) predicted ED and it might be helpful in diagnosing erectile dysfunction. The study was published on May 5, 2019, in the Urology Journal.

Related Links:
Ordu University


New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Urine Analyzer
respons® UDS100
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: The GenoPredict assay from Predicta Biosciences is available to Tempus Life Sciences partners to support exploratory research and clinical development programs (photo courtesy of Shutterstock)

Partnership Expands Ultrasensitive WGS Assay for for Hematologic Malignancies and MRD Monitoring

Tempus AI and Predicta Biosciences announced the commercial expansion of a co-branded whole‑genome sequencing assay GenoPredicta, which is intended for comprehensive genomic characterization of hematologic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.